Sinocelltech Group Limited (688520.SS)
- Previous Close
49.18 - Open
48.55 - Bid 48.94 x --
- Ask 48.99 x --
- Day's Range
48.23 - 50.45 - 52 Week Range
31.07 - 50.45 - Volume
8,408,754 - Avg. Volume
3,618,364 - Market Cap (intraday)
21.795B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
244.70 - EPS (TTM)
0.20 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Sinocelltech Group Limited, a biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and innovative vaccines in China. The company offers Anpingxi an antibody drug and anti-tumor product; Anjiayin for the treatment of the rare disease hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and mutant strain recombinant protein vaccines SCTV01C and SCTV01E. Its pipeline products include SCT630 used for the treatment of autoimmune diseases; SCT510 for the treatment of solid tumors; SCT-I10A, a monoclonal antibody injection which is in phase 3 trials for the treatment of solid tumors; SCTV01, a new generation vaccine which is in phase 3 trials for the treatment of corona virus; SCT510 for the treatment of solid tumors; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000, which is in phase 3 clinical trials for the treatment of human papillomavirus, as well as SCTA01 which is in phase 2/3 clinical research trials for the treatment of SARS COV-2. The company was founded in 2007 and is based in Beijing, China. The company operates as a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.
www.sinocelltech.comRecent News: 688520.SS
View MorePerformance Overview: 688520.SS
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is 000001.SS (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688520.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688520.SS
View MoreValuation Measures
Market Cap
21.79B
Enterprise Value
24.22B
Trailing P/E
244.70
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.71
Price/Book (mrq)
106.70
Enterprise Value/Revenue
10.01
Enterprise Value/EBITDA
123.63
Financial Highlights
Profitability and Income Statement
Profit Margin
4.20%
Return on Assets (ttm)
8.19%
Return on Equity (ttm)
--
Revenue (ttm)
2.42B
Net Income Avi to Common (ttm)
101.52M
Diluted EPS (ttm)
0.20
Balance Sheet and Cash Flow
Total Cash (mrq)
312.89M
Total Debt/Equity (mrq)
1,378.37%
Levered Free Cash Flow (ttm)
-357.61M